Goldman Sachs Group, Inc. (The) reiterated their sell rating on shares of AstraZeneca plc (LON:AZN) in a research report released on Friday morning. Goldman Sachs Group, Inc. (The) currently has a GBX 3,900 ($50.93) target price on the biopharmaceutical company’s stock.

Other equities analysts have also recently issued research reports about the company. Liberum Capital reiterated a buy rating and set a GBX 5,100 ($66.60) target price on shares of AstraZeneca plc in a report on Tuesday, March 21st. Deutsche Bank AG restated a buy rating and set a GBX 5,500 ($71.82) price objective on shares of AstraZeneca plc in a research note on Tuesday, March 21st. Berenberg Bank increased their price objective on shares of AstraZeneca plc from GBX 5,450 ($71.17) to GBX 5,670 ($74.04) and gave the stock a buy rating in a research note on Monday, March 20th. Societe Generale restated a buy rating on shares of AstraZeneca plc in a research note on Thursday, March 23rd. Finally, Kepler Capital Markets restated a buy rating and set a GBX 5,000 ($65.29) price objective on shares of AstraZeneca plc in a research note on Friday, April 21st. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have given a buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of GBX 5,251.80 ($68.58).

AstraZeneca plc (LON AZN) traded up 0.58% during mid-day trading on Friday, reaching GBX 5069.00. The company had a trading volume of 1,763,249 shares. The firm’s 50-day moving average price is GBX 5,259.89 and its 200-day moving average price is GBX 4,769.91. AstraZeneca plc has a 12 month low of GBX 3,996.00 and a 12 month high of GBX 5,520.00. The stock’s market cap is GBX 64.17 billion.

COPYRIGHT VIOLATION WARNING: This article was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/07/18/astrazeneca-plc-lonazn-earns-sell-rating-from-goldman-sachs-group-inc-the.html.

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.